Larinate 60mg Injection- 1 vial

Details

Larinate Injection contains Artesunate, an essential drug in the fight against malaria. It is the recommended first-line intravenous or intramuscular treatment for severe and complicated *Plasmodium falciparum* malaria, known for its rapid action in reducing parasite load and minimizing mortality risk, especially in children and adults with cerebral malaria.

Available Forms/Strengths

This product is supplied as a sterile powder for injection, packaged with a solvent for reconstitution. It is available in three critical strengths to suit dosing requirements across all patient weights:

• Larinate Injection 30mg: Typically used for pediatric and lower-weight dosing.
• Larinate Injection 60mg: Standard intermediate strength for flexible adult and adolescent dosing.
• Larinate Injection 120mg: Higher strength for heavier adult patients, ensuring accurate high-dose administration.

Main Uses (Indications)

Larinate (Artesunate) is indicated exclusively for the management of severe malaria, defined by symptoms such as:

• Cerebral malaria (impaired consciousness/coma).
• Severe anaemia.
• Renal impairment or acute kidney injury.
• Acidosis or respiratory distress.
• High parasite density (>10% parasitaemia).

Usage Instructions (Itemized with Administration)

1. Preparation: The powder must be **reconstituted with the supplied solvent** (usually 5% Sodium Bicarbonate solution) immediately before use by a trained healthcare professional.
2. Dosing: Dosage is determined by the patient’s **body weight** and is given intravenously (IV) or intramuscularly (IM) at 0, 12, and 24 hours, followed by once daily until the patient can switch to an oral Antimalarial Combination Therapy (ACT).
3. Setting: STRICTLY administered in a hospital or clinical environment under continuous supervision.

Potential Risks and Adverse Events

The benefits of using Artesunate in severe malaria far outweigh the risks. However, potential adverse events that require close monitoring include:

• **Delayed Haemolysis:** Destruction of red blood cells, which may occur 1 to 4 weeks after treatment completion, requiring follow-up monitoring.
• Common effects: Mild gastrointestinal disturbance, dizziness, or injection site pain.

Warnings/Precautions

• Trained Personnel: Administration of Larinate requires a skilled professional due to the critical nature of the patient’s condition and the reconstitution process.
• Contraindications: There are no absolute contraindications to using Larinate in severe malaria, as it is a life-saving intervention.
• Post-Treatment: Patients must receive a full course of follow-up oral therapy (ACT) after the initial parenteral treatment is complete.

Quick Product Facts Table

Mechanism of Operation

Larinate’s effectiveness is based on the rapid action of **Artesunate**, which is quickly metabolized to Dihydroartemisinin (DHA). The malaria parasite, residing within red blood cells, concentrates iron (heme) in its food vacuole. DHA interacts with this high iron concentration, leading to the massive and immediate production of **highly toxic free radicals** and oxidative stress. This process rapidly destroys the asexual blood-stage parasites, causing a faster decline in parasite numbers than any other drug and dramatically improving patient survival.

Copyright: Haki miliki zote zimehifadhiwa.